Sulodexide Tested to Prevent Psoriasis Returning After Biologic Treatment
Tests sulodexide against placebo in adults with plaque psoriasis who stopped biologic therapy.
Plain-language title generated from the registry record
Registry title: Sulodexide in Controlling the Recurrence of Psoriasis
Key facts
- Where
- Xi'an, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06982196, who can take part
Where in China
- xjjing HospitalXi'an, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT06982196
- Record updated
- 21 May 2025
- Original description
This is a multicenter, randomized, double-blinded，controlled clinical trial. The purpose of the study is to evaluate the efficacy and safety of Sulodexide versus placebo in preventing psoriasis recurrence in patients with plaque psoriasis who have discontinued biologic therapy after achieving clinical cure.Read full original descriptionShow less
Multicenter, Randomized, Double-blinded，Controlled Clinical Study to Evaluate the Efficacy and Safety of Sulodexide in Controlling the Recurrence of Psoriasis
This is a multicenter, randomized, double-blinded，controlled clinical trial. The purpose of the study is to evaluate the efficacy and safety of Sulodexide versus placebo in preventing psoriasis recurrence in patients with plaque psoriasis who have discontinued biologic therapy after achieving clinical cure.
Inclusion: Age is 18-65 years old and gender is not limited; Clinical diagnosis consistent with moderate to severe plaque psoriasis; After receiving standardised treatment with strychnicolizumab for 3 months to achieve complete clearing of skin lesions (in accordance with PASI 100 or PGA 0), and then continuing the treatment for 6 months without symptomatic relapse to satisfy the criteria for discontinuation of the drug and discontinuing strychnicolizumab (refer to the recommendations of 'Guidelines for the treatment of psoriasis with biologics in China (2021 edition)'); Voluntarily participate in the study and sign the informed consent form before the start of the study.
Exclusion: Have received or currently require treatment with other anticoagulant drugs such as sulodexide drugs within the last 9 months (e.g. argatroban, bivalirudin, dabigatran etexilate, desirudin, lepirudin, aspirin, etc.); Treatment with other biological agents within the last 9 months; Highly allergic or with a history of severe allergies; allergy to heparin or heparin analogues; or known/suspected allergy to one of the components of the investigational drug; Suffering from severe systemic or localised infections within the last 6 months; Those with bleeding tendency or suffering from bleeding disorders; The presence of malignant tumours, or postoperative tumour patients and those at high risk of tumours; Infection with other diseases such as Human Immunodeficiency Virus (HIV); Serious, progressive, uncontrolled disorders of vital organs and systems (including cardiovascular, hepatic, pulmonary, and renal) and other diseases that, in the opinion of the investigator, are not suitable for participation in the study in combination; Known presence of alcoholism, drug dependence, or psychiatric disorders; A positive serum or urine pregnancy test in a female of childbearing potential during the Screening Period; Clinically significant abnormal values on screening tests as determined by the investigator; Pregnant women or women of childbearing potential who intend to become pregnant or breastfeeding during the trial period; Currently participating in another clinical study or have participated in another clinical study within 3 months; Known or suspected to be unable to complete the trial due to poor adherence; Who, in the judgement of the investigator, are unsuitable for participation in this clinical study.